secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0000950170-23-049926
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Kintara Therapeutics gets Nasdaq delisting notice; equity at $731K vs $2.5M requirement
--------------------------------------------------------------------------------

- Received Nasdaq notice on Sept 20, 2023 for non-compliance with minimum stockholders' equity requirement of $2.5M; reported equity of $731,000 in FY 2023 10-K.
- Company has until Nov 6, 2023 to submit a plan to regain compliance; if accepted, may get up to 180-day extension.
- Also does not meet alternative listing standards: market value of listed securities ≥$35M or net income $500K from continuing operations.
- Common stock continues trading on Nasdaq under KTRA during compliance process; delisting could reduce liquidity and capital raising ability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017023049926/0000950170-23-049926-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017023049926/ktra-20230920.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-049926

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer